Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
Three subtypes of human (h) arginine vasopressin (AVP) receptors, hV1A, hV1B and hV2, were stably expressed in Chinese hamster ovary (CHO) cells and characterized by [3H]-AVP binding studies. In addition, the coupling of the expressed receptor protein to a variety of signal transduction pathways was investigated. Scatchard analysis of saturation isotherms for the specific binding of [3H]-AVP to membranes, prepared from CHO cells transfected with hV1A, hV1B and hV2 receptors, yielded an apparent equilibrium dissociation constant (Kd) of 0.39, 0.25 and 1.21 nM and a maximum receptor density (Bmax) of 1580 fmol mg(-1) protein, 5230 fmol mg(-1) protein and 7020 fmol mg(-1) protein, respectively. Hill coefficients did not differ significantly from unity, suggesting binding to homogenous, non-interacting receptor populations. Pharmacological characterization of the transfected human AVP receptors was undertaken by measuring the relative ability of nonpeptide AVP receptor antagonists, YM087, OPC-21268, OPC-31260, SR 49059 and SR 121463A, to inhibit binding of [3H]-AVP. At hV1A receptors, the relative order of potency was SR49059>YM087>OPC-31260>SR 121463A> >OPC-21268 and at hV2 receptors, YM087=SR 121463A>OPC-31260>SR 49059> >OPC-21268. In contrast, the relative order of potency, at hV1B receptors, was SR 49059> >SR 121463A=YM087=OPC-31260=OPC-21268. In CHO cells expressing either hV1A or hV1B receptors, AVP caused a concentration-dependent increase in intracellular Ca2+ concentration ([Ca2+]i) with an EC50 value of 1.13 nM and 0.90 nM, respectively. In contrast, stimulation of CHO cells expressing hV2 receptors resulted in an accumulation of cyclic AMP with an EC50 value of 2.22 nM. The potency order of antagonists in inhibiting AVP-induced [Ca2+]i or cyclic AMP response was similar to that observed in radioligand binding assays. In conclusion, we have characterized the pharmacology of human cloned V1A, V1B and V2 receptors and used these to determine the affinity, selectivity and potency of nonpeptide AVP receptor antagonists. Thus they may prove to be a valuable tool in further examination of the physiological and pathophysiological roles of AVP.
Tahara
A
A
Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Saito
M
M
Sugimoto
T
T
Tomura
Y
Y
Wada
K
K
Kusayama
T
T
Tsukada
J
J
Ishii
N
N
Yatsu
T
T
Uchida
W
W
Tanaka
A
A
D000818:Animals; D001552:Benzazepines / Q000378:metabolism; D001667:Binding, Competitive; D016466:CHO Cells; D002118:Calcium / Q000378:metabolism; D006224:Cricetinae; D000242:Cyclic AMP / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000378:metabolism; D009025:Morpholines / Q000378:metabolism; D010880:Piperidines / Q000378:metabolism; D011759:Pyrrolidines / Q000378:metabolism; D015363:Quinolones / Q000378:metabolism; D017483:Receptors, Vasopressin / Q000145:classification / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D013141:Spiro Compounds / Q000378:metabolism; D014162:Transfection; D014316:Tritium
D001552:Benzazepines; D007211:Indoles; D009025:Morpholines; D010880:Piperidines; D011759:Pyrrolidines; D015363:Quinolones; D017483:Receptors, Vasopressin; D013141:Spiro Compounds; C106389:conivaptan; D014316:Tritium; C068644:OPC 21268; C076251:mozavaptan; C103281:satavaptan; C082134:relcovaptan; D000242:Cyclic AMP; D002118:Calcium